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Low mean perfusion pressure is a risk
factor for progression of acute kidney
injury in critically ill patients – A
retrospective analysis
Marlies Ostermann1* , Anna Hall2 and Siobhan Crichton3
Abstract
Background: The aim was to investigate whether mean perfusion pressure (MPP) calculated as the difference
between mean arterial pressure (MAP) and central venous pressure (CVP) was associated with risk of progression
from AKI I to AKI III in critically ill patients.
Methods: Retrospective analysis of adult patients admitted to a multi-disciplinary adult intensive care unit
(ICU) between July 2007 and June 2009 who developed AKI I and in whom advanced haemodynamic monitoring was
initiated within 12 h of diagnosis of AKI I. We compared patients with a MPP above and below the median value in the
first 12 h of diagnosis of AKI. Multivariable logistic regression analyses were performed to identify independent risk
factors for progression to AKI III, to explore the impact of MAP and CVP separately, and to investigate the impact of MPP
in pre-defined sub-groups.
Results: Among 2118 ICU patients, 790 patients (37%) developed AKI I of whom 205 underwent advanced
haemodynamic monitoring within 12 h of AKI stage I. Their median MPP was 59 mmHg. AKI I patients with a
MPP ≤59 mmHg had a significantly higher risk of progressing to AKI stage III (48.6% versus 34%, respectively;
p = 0.0034). This association was stronger in patients with ischemic heart disease, congestive cardiac failure or
without pre-existing hypertension and in patients with a MAP <65 mmHg for >1 h. As individual components, a raised
CVP was independently associated with progression to AKI stage III but MAP alone was not an independent risk factor
for AKI progression.
Conclusion: MPP <60 mmHg was independently associated with AKI progression. CVP was the key component of MPP.
Keywords: Acute kidney injury, Central venous pressure, Mean perfusion pressure, Haemodynamics, Risk of progression
Background
Acute kidney injury (AKI) is one of the most com-
mon complications of critical illness affecting 50–60%
of patients admitted to the Intensive Care Unit (ICU)
[1, 2]. It is associated with serious short- and long
term complications, including increased mortality and
contributes to significant healthcare costs [3–5].
Worldwide, opportunities are sought to prevent AKI
and to reduce the risk of progression.
Haemodynamic regulation of renal blood flow and
renal venous pressure are key determinants of renal
function. In healthy individuals without systemic hyper-
tension, intrarenal blood flow is auto-regulated at renal
perfusion pressures between 60 and 100 mmHg [6].
During critical illness, these processes may be compro-
mised. A raised central venous pressure (CVP) and the
resultant increased backward pressure also negatively
impacts on renal function, mainly due to renal conges-
tion and increased intra-renal pressure resulting in a fall
in glomerular filtration rate (GFR) [7–10]. Most
evidence stems from studies in patients with cardiovas-
cular disease where an association between renal venous
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congestion and the development of AKI has been repeat-
edly shown [11–16].
To date, there are no established techniques to
evaluate and monitor intrarenal blood flow and renal
perfusion pressures directly [17]. There are also no
reliable means to predict intrarenal haemodynamics
from systemic arterial pressures. It has been suggested
that mean perfusion pressure (MPP) may serve as a
surrogate. MPP is calculated as the difference between
systemic mean arterial pressure (MAP) and CVP, ie
MPP = MAP – CVP [18] Previous studies have
shown that a lower MPP was associated with an
increased risk of developing AKI [19]. It remains
unknown whether MPP also affects the risk of
progression in patients with established AKI.
Methods
Aims
The aims of this study were.
i) to explore whether patients with a new diagnosis of
AKI stage I and a calculated MPP below the median
value had a higher risk of progression to AKI stage III
than AKI I patients with a MPP above the median;
ii) to investigate whether MAP or CVP as individual
components of MPP have a greater impact on risk of
progression from AKI stage I to AKI stage III.
Setting
Guy’s & St Thomas’ NHS Foundation Hospital is a
tertiary care centre with a 43-bed, level 3 multi-
disciplinary adult intensive care unit (ICU). The ICU has
a fully computerised electronic patient record system
where all data are recorded at the time of generation.
Patient and study design
In this ancillary investigation of a previously reported
study [20, 21], we retrospectively analysed a database of
all patients admitted to the ICU between July 2007 and
June 2009. Using the creatinine criteria of the AKI
Network (AKIN) classification, we retrospectively identi-
fied patients with AKI stage 1 (AKI I) (i.e., rise in serum
creatinine by ≥0.3 mg/dl [≥26.4 μmol/L] or by ≥50%
from baseline in ≤48 h) [22]. We only used serum
creatinine results obtained during the relevant
hospitalization to diagnose AKI in order to comply with
the 48-h time window and considered the lowest
creatinine result as the baseline value. We selected all
patients in whom advanced haemodynamic monitoring
had been initiated for clinical reasons within 12 h of the
patient meeting the criteria for AKI I.
All patients had an internal jugular vein central venous
catheter. Patients with a renal transplant, re-admissions,
and patients who left the ICU within 24 h of diagnosis
of AKI I or developed AKI stage III within 12 h of
diagnosis of AKI I were excluded. The outcome of
interest was progression to AKI stage III.
Data collection
As previously reported [20], we collected demographics,
co-morbidities and Sequential Organ Failure Assessment
(SOFA) score on admission to ICU and day of AKI I.
We also recorded routine haemodynamic parameters
obtained by advanced haemodynamic monitoring and
arterial lactate concentration during the first 12 h period
after diagnosis of AKI I. The MAP and CVP obtained
during the first set of advanced haemodynamic monitor-
ing were used to calculate the MPP. Indexed oxygen
delivery (DO2I) was calculated as DO2I = 1.34 X haemo-
globin concentration X oxygen saturation X cardiac
index. Cumulative fluid balance was determined from all
recorded fluid input and output data.
Statistics
MPP was calculated as the difference between MAP and
CVP taken during the immediate 12-h period after
diagnosis of AKI I. Characteristics of patients were
summarised as median (interquartile range), mean
(standard deviation) or frequency (percentage) and
compared between patients with a MPP above and
below the median value using Mann Whitney, t-test or
chi-square tests as appropriate.
The association between MPP and the odds of
progressing to AKI III was explored by multivariable
logistic regression analysis with adjustment for factors
previously shown to be associated with risk of progres-
sion, ie. age, indexed oxygen delivery, arterial lactate
concentration, cumulative fluid balance and SOFA score
[20, 21]. The odds ratios (OR) and respective 95% confi-
dence intervals (CI) were calculated. To explore the
possibility of a non-linear relationship between MPP and
AKI progression, models were fitted allowing for a quad-
ratic, then cubic relationship between MPP and odds of
progression. A further model included MPP categorised
into bands of width 10 mmHg. Models were also strati-
fied by presence of pre-existing hypertension, ischaemic
heart disease (IHD), congestive cardiac failure (CCF),
CVP >15 mmHg or severe hypotension (ie. MAP
<65 mmHg for 1 h or more).
The individual impact of CVP and MAP on the effect of
MPP was explored using both parameters as continuous
measures. The model was adjusted for relevant confound-
ing factors.
Stata 13MP was used to conduct the analyses.
Results
Between July 2007 – June 2009, 2118 patients were
admitted to the ICU of whom 790 patients (37%) met
the criteria for new onset of AKI I. Sixty-nine patients
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were excluded. (Fig. 1) Among the remaining 721
patients, haemodynamic monitoring using pulse induced
contour or lithium dilution cardiac output technique
was initiated by the clinical team in 210 patients within
12 h of AKI I. Five patients were excluded from this
analysis as they died before AKI I resolved or
progressed. The median age of the remaining 205
patients was 70 years, 67% were male and 44% had
underlying IHD or CCF. (Table 1) The median MPP was
59 mmHg.
At baseline, there was a significantly larger propor-
tion of patients admitted with acute neurological dis-
orders among those with MPP >59 mmHg. (Table 1)
There was no other significant difference between
patients with a MPP ≤59 mmHg versus MPP
>59 mmHg following AKI I.
On day of AKI I, patients with MPP ≤59 mmHg
had a significantly higher SOFA score (mean = 9.2
versus 8.1; p = 0.003). (Table 1) Within the initial
12 h period after diagnosis of AKI I, patients with a
MPP ≤59 mmHg had a significantly higher CVP
(median = 14 versus 11, p < 0.001) and required
vasopressor support more often (94.3% versus 83%;
p = 0.010). (Table 1).
Progression to AKI III
AKI I patients with a MPP ≤59 mmHg during the initial
12 h after diagnosis of AKI I had a significantly higher
risk of progression to AKI III compared to AKI I
patients with MPP >59 mmHg (48.6% versus 34%,
respectively; p = 0.0034). Multivariable regression
analysis confirmed that SOFA score on day of AKI I and
Fig. 1 Patient flow. Abbreviations: AKI = acute kidney injury; ESRD = end stage renal disease; ICU = intensive care unit; MPP = mean perfusion pressure
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MPP, DO2I and first arterial lactate concentration within
12 h of diagnosis of AKI I were independently associated
with AKI progression. (Table 2) For each one point
increase in MPP, the odds of progression to AKI III
decreased by 4.5% (OR = 0.96; 95% CI 0.92–0.996;
p = 0.031). In sensitivity analyses there was no evidence
of a non-linear relationship between MPP and odds of
progression.
Subgroup analysis
It was hypothesised that the effect of MPP on risk of
progression to AKI III may differ in high-risk patients,
including those with cardiac disease, pre-existing
hypertension, a CVP >15 mmHg or a MAP <65 mmHg
for more than 1 h in the 12-h period following diagno-
sis of AKI I. Subgroup analyses confirmed that MPP
was significantly associated with odds of progression
to AKI III in patients with IHD or CCF, in patients
with MAP <65 mmHg for >1 h and also in patients
without pre-existing hypertension. (Table 3) Tests of
interaction between each of these variables and MPP
were statistically non-significant (p > 0.1).
Comparison of impact of CVP and MAP
Multivariable analysis using CVP and MAP as individual
components showed that CVP was an independent risk
Table 1 Patient characteristics
Total cohort n = 205 MPP ≤59 mmHg n = 105 MPP >59 mmHg n = 100 p-value
Age, median (IQR) 70 (56–77) 71 (56–78) 70 (57–78) 0.66
Male gender, n (%) 138 (67.3) 72 (68.6) 66 (66.0) 0.70
Comorbidities
IHD / CHF, n (%) 90 (43.9) 45 (42.9) 45(45.0) 0.76
Diabetes, n (%) 38 (18.5) 17 (16.2) 21 (21.0) 0.38
Hypertension, n (%) 79 (38.5) 35 (33.3) 44 (44.0) 0.12
CKD, n (%) 25 (12.2) 12 (11.4) 13 (13.0) 0.73
COPD, n (%) 26 (12.7) 11 (10.5) 15 (15.0) 0.33
CLD, n (%) 11 (5.4) 6 (5.7) 5 (5.0) 0.82
Admission diagnosis
Post-surgical, n (%) 72 (35.1) 34 (23.3) 38 (38.0) 0.88
Cardiac emergency, n (%) 53 (25.9) 29 (27.6) 24 (24.0)
Sepsis, n (%) 35 (17.1) 18 (17.1) 17 (17.0)
Respiratory emergency, n (%) 34 (16.6) 17 (16.2) 17 (17.0)
Gastrointestinal emergency, n (%) 7 (3.4) 5 (4.8) 2 (2.0)
Other, n (%) 3 (1.5) 1 (1.0) 2 (2.0)
Parameters on admission to ICU
SOFA score, mean (SD) 7.1 (2.8) 7.5 (2.6) 6.8 (2.9) 0.09
APACHE II score, median (IQR) 18 (14–21) 17 (14–21) 18 (13–21) 0.80
Parameters on day of AKI I
SOFA score, mean (SD) 8.7 (2.7) 9.2 (2.7) 8.1 (2.7) 0.003
Cumulative fluid balance [ml], median (IQR) 2363 (52–3812) 2149 (802–3643) 2568 (994–4116) 0.234
Sepsis, n (%) 122 (59.8) 57 (54.8) 65 (65) 0.138
Parameters within 12 h of diagnosis of AKI I
DO2I [ml/min/m
2], median (IQR) 362 (277–4836) 347 (270–459) 377 (296–494) 0.132
Arterial lactate [mmol/L], median (IQR) 1.7 (1.3–2.6) 1.8 (1.2–2.6) 1.7 (1.3–2.6) 0.833
MAP <65 mmHg for >1 h, n (%) 107 (52.2) 74 (70.5) 33 (33.0) <0.001
MAP during 12 h [mmHg], median (IQR) 73 (69–78) 69 (66–73) 78 (73–83) <0.001
CVP [mmHg], median (IQR) 14 (10–18) 14 (11–18) 11 (9–15) <0.001
Vasopressor use, n (%) 182 (88.8) 99 (94.3) 83 (83.0) 0.01
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, AKI acute kidney injury, CCF congestive cardiac failure, CKD chronic kidney disease, COPD
chronic obstructive pulmonary disease, CLD chronic liver disease, CVP central venous pressure, DO2I oxygen delivery index, IHD ischaemic heart disease,
IQR interquartile range, MAP mean arterial pressure, MPP mean perfusion pressure, SD standard deviation, SOFA sequential organ failure assessment
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factor for progression to AKI III (OR 1.08; 95% CI
1.02–1.14; p = 0.005) after controlling for age, oxygen
delivery index, arterial lactate, cumulative fluid
balance and SOFA score. In contrast, MAP during
the 12 h period after diagnosis of AKI I was not
independently associated with risk of progression
(OR = 0.96, 95% CI = 0.92–1.00, p = 0.079). Further
analyses to explore whether the effect of CVP differed
by MAP showed that the interaction was statistically
not significant (OR = 1.00; 95% CI 0.99–1.01;
p = 0.88).
Discussion
This retrospective single-centre study shows that MPP
during the 12 h period following diagnosis of AKI stage
I is independently associated with risk of progression to
AKI III. The association between MPP and progression
was particularly strong in patients with IHD or CCF,
those without pre-existing hypertension and in patients
with a MAP <65 mmHg for >1 h. CVP was the key
component of the MPP with independent impact on risk
of progression to AKI III whereas MAP was not
independently associated with progression.
The finding that elevated CVP can lead to renal
dysfunction was first demonstrated in experimental
animal studies [8, 23, 24]. Potential mechanisms include
transmission of back pressure to the renal veins,
increased pressure along the renal vascular tree leading
to compression of tubules and decreased net pressure
gradient across the glomerulus, ultimately resulting in
decreased glomerular filtration.
In humans, the evidence for an association between
CVP and AKI stems predominantly from patients with
cardiac disease [15]. A sub-analysis of the ESCAPE
(Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness) study in
patients with decompensated heart failure revealed that
among the haemodynamic parameters measured only
right atrial pressure correlated with renal function [11].
A different study in 145 patients with acute decompen-
sated heart failure admitted to the Cleveland Clinic
confirmed a direct progressive association between base-
line CVP and incidence of AKI: when CVP reached >16
or >24 mmHg, the incidence of AKI was 59 or 75%,
respectively [12]. Other haemodynamic variables were
not independent risk factors for AKI. In cardiac surgery
cohorts where systemic venous congestion is a hallmark
feature, such as in patients with right valve pathology,
AKI is also very prevalent [15]. Williams et al. analysed
the data of 1497 patients who underwent coronary artery
bypass grafting and had either an ejection fraction <40%
or an age >65 years [16]. They showed that for CVP
increments of 5 mmHg above the threshold of 9 mmHg,
the risk-adjusted odds ratio for AKI was 1.3 (95% CI
1.01–1.65; p = 0.045). In congestive heart failure, the
increased backward pressure appears to propagate in all
districts of the venous system, including renal veins.
We found that the relationship between MPP and AKI
progression was primarily based on an independent
association between CVP and AKI. In fact, more than
150 years ago, Ludwig and colleagues made similar
observations [21]. They showed that if pressure in the
renal veins was raised by about 10 mmHg, urine flow
was reduced. They attributed this to the histological
observation that an increase of venous pressure was
associated with distended venules surrounding the distal
ends of the tubules resulting in obliteration of the lumen
of the tubules. In 1931, using animal models, Winton
and colleagues showed that an increase in venous pres-
sure resulted in greater diminution of intrarenal blood
flow than a corresponding change in arterial pressure
Table 3 Subgroup analyses: Adjusted association between MPP
and progression to AKI III
Patient cohort OR (95% CI)a p-value
No IHD / CCF 0.98 (0.92–1.04) 0.49
IHD / CCF 0.92 (0.86–0.98) 0.019
MAP not <65 mmHg for >1 h 0.96 0.90–1.02) 0.23
MAP <65 mmHg for >1 h 0.93 (0.87–0.98) 0.013
CVP ≤15 mmHg 0.94 (0.87–1.01) 0.08
CVP >15 mmHg 0.98 (0.92–1.04) 0.47
No pre-existing hypertension 0.93 (0.88–0.99) 0.032
Pre-existing hypertension 0.96 (0.90–1.03) 0.259
Abbreviations: AKI acute kidney injury, CCF congestive cardiac failure, IHD
ischaemic heart disease, CVP central venous pressure, MAP mean arterial
pressure, MPP mean perfusion pressure, OR odds ratio, CI confidence interval
arepresents the change in odds of progression to AKI III associated with a one
unit increase in MPP adjusted for age, oxygen delivery index, arterial lactate
concentration, cumulative fluid balance and SOFA score
Table 2 Multivariable analysis: Risk factors for progression from
AKI I to AKI III
Parameter OR (95% CI)a p-value
First arterial lactate following
diagnosis of AKI I [mmol/L]
1.45 (1.12–1.89) 0.005
SOFA score on day of AKI I 1.20 (1.05–1.37) 0.01
First DO2I in 12 h period after
diagnosis of AKI I [ml/min/m2]
0.997 (0.994–0.99) 0.01
First calculated MPP 0.995 (0.92–0.99) 0.03
Age [years] 1.02 (0.997–1.05) 0.09
Cumulative fluid balance on
day of AKI I [ml]
1.00 (0.99–1.00) 0.98
MAP <65 mmHg for >1 h in
first 12 h after diagnosis of AKI I
0.97 (0.48–1.96) 0.93
Abbreviations: CI confidence interval, DO2I oxygen delivery index, MAP mean
arterial pressure, MPP mean perfusion pressure, OR odds ratio, SOFA sequential
organ failure assessment
acontrolled for age, oxygen delivery index, arterial lactate concentration,
cumulative fluid balance and SOFA score
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[8]. Our finding that a rise in CVP was independently
associated with progression from AKI I to AKI III
whereas a fall in MAP in isolation was not an independ-
ent risk factor, complements these observations from
100 years ago.
To date, studies have focussed on the link between
CVP and risk of AKI. To our best knowledge, our
study is the first which analysed patients who had
already developed AKI and explored the association
between MAP, CVP and risk of progression to severe
AKI. Physiologically, our conclusion that a reduced
MPP is associated with an increased risk of progres-
sion makes sense. The finding that a higher CVP had
a greater impact on the effects of progression than a
lower MAP is also supported by basic physiology
studies in the literature [8, 24].
Measuring renal congestion by imaging is challenging
at the bedside and requires extensive patient manipula-
tion, which, in the critically ill patient greatly reduces
the practical applicability of any given technique [17].
Based on our data, we suggest that a calculated MPP
≤59 mmHg in the early phase of AKI I may serve as a
surrogate marker of increased risk for progression to
AKI stage III. Although we did not study any potential
interventions, our data also imply that in cardiac
patients with AKI stage I and a MPP ≤59 mmHg, further
fluid loading may not be advisable if this leads to an
increase in CVP. Clearly, more studies are necessary to
investigate whether MPP could serve as tool to assess
the risk of AKI and a guide for potential therapeutic
manipulation, including attempts to reduce CVP.
Our analysis has all limitations of a retrospective single
centre study with a heterogeneous patient population. We
also acknowledge that we calculated MPP but did not
perform invasive renal pressure monitoring or imaging
techniques for comparison. Second, we only analysed
patients in whom haemodynamic monitoring had been
performed for clinical reasons. Third, we defined AKI by
serum creatinine results obtained during hospitalisation
only. We did not use urine output criteria and may have
missed cases with AKI stage I. Finally, the study design
was non-interventional, and the association between MPP
and progression of AKI does not prove a causal relation-
ship. Whether actively increasing MPP by raising MAP or
lowering CVP may reduce the risk of progression to AKI
III needs to be evaluated in future studies.
Conclusions
Our study showed that MPP ≤59 mmHg is independ-
ently associated with progression of AKI in ICU and this
association is particularly strong in patients with IHD/
CCF, those without pre-existing hypertension and in
patients with MAP <65 mmHg for >1 h. A raised CVP
had a greater impact on AKI progression than MAP.
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